60501-41-9

Usage

Uses

Used in Adhesives Industry:
(Z)-[(octadec-9-enyloxy)methyl]oxirane is used as a bonding agent for creating strong and flexible adhesives. Its ability to form robust bonds makes it suitable for various applications within the industry.
Used in Coatings Industry:
(Z)-[(octadec-9-enyloxy)methyl]oxirane is used as a component in the production of coatings, providing resistance to corrosion and chemicals. This property makes it valuable for creating durable and protective coatings for various surfaces.
Used in Plastics Industry:
(Z)-[(octadec-9-enyloxy)methyl]oxirane is used as a raw material in the manufacturing of plastics. Its versatility in forming bonds and its resistance to corrosion and chemicals contribute to the development of high-quality plastic products.
Used in Pharmaceutical and Biotechnology Industry:
(Z)-[(octadec-9-enyloxy)methyl]oxirane is used as a building block for the synthesis of bioactive molecules. Its potential applications in this field highlight its importance in creating new and innovative pharmaceutical and biotechnological products.
It is important to handle and use (Z)-[(octadec-9-enyloxy)methyl]oxirane with care, as it may be toxic and harmful if not properly managed.

InChI:InChI=1/C21H40O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-22-19-21-20-23-21/h9-10,21H,2-8,11-20H2,1H3/b10-9-

Upstream product

• 143-28-2 oleoyl alcohol 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 106-89-8 epichlorohydrin 
• 213738-39-7 1-O-oleyl-rac-glycero-3-p-toluenesulfonate 
• 118712-54-2 glycidyl p-toluenesulfonate 

Downstream Products

• 593-31-7 rac-1-(Z-9-octadecenyl)glycerol 
• 13051-29-1 monoacetyl pentaerythritol 

Relevant academic research and scientific papers

Synthesis of new deuterated lipid probes for membrane fluidity measurements

New phosphatidylcholine analogs have been synthesized in order to be used as probes for membrane fluidity measurements in 2H-NMR experiments. A 1,3-asymmetrical diether glycerophosphatidylcholine pentadeuterated at the glycerol moiety is elaborated starting from propiolic acid in a 8-steps procedure whereas the corresponding monodeuterated compound is prepared from epibromohydrin.

COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS

Compounds, pharmaceutical compositions, and methods for treating cancer, in particular brain cancer, are provided, including amphiphilic fatty acid/alcohol ethers (AIPs) comprising endocannabinoid and FABP motifs covalently linked to a beta-adrenoreceptor antagonist motif in one molecule. The invention includes methods for inhibiting growth of brain cancer cells by contacting the compound(s) with brain cancer cells. The invention provides a method for treating both brain cancer and brain cancer metastases, and for suppression of regrowth of brain cancer cells after radiation, surgical treatment, or chemotherapy of brain cancer. The invention also comprises an optimized chemical synthesis of the AIP compounds and methods of using the compounds, alone or in combination with another agent, for suppressing the growth of brain cancer cells, and enhancing survival of normal CNS cells, or improving recuperation from radiation, surgical or chemotherapy.

Synthesis of natural 1- O -alkylglycerols: A study on the chemoselective opening of the epoxide ring by onium quaternary salts (N and P) and ionic liquids

A chemoselective route for the synthesis of 1-O-alkylglycerols chimyl (1), batyl (2), and selachyl (3) is reported. These compounds can be naturally isolated from shark liver oil and the skin of animals such as stingrays and chimeras and exhibit potential anti-fouling activity. The synthetic approach developed in this work included two distinct methods of preparation. The first was based on solvent-free reactions catalyzed by onium quaternary salts (N and P) and ionic liquids; the second methodology was based on a series of one-pot reactions.

DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY

Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.

LIPID COMPOUNDS FOR SUPRESSION OF TUMORIGENESIS

The present invention provides compounds, or pharmaceutically acceptable salts or analogs thereof, which exhibit anti-tumor activity. The present invention also includes methods for inhibiting the growth of cancer cells by contacting an effective amount of a compound of the present invention with the cancer cells in vitro or in vivo.

MULTI-CHAIN LIPOPHILIC POLYAMINES

There are provided multi-chain lipophilic polyamine compounds and derivatives thereof, pharmaceutical formulations comprising the same, method of making and using said compounds or formulations.

Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof

The invention provides anti-apoptotic compositions lysophosphatidic acids and methods for making and using the compositions. Such compositions can also contain LPA potentiating agents, including proteins, lipid membrane structures and polymers such as polyethylene glycols. The compositions can additionally contain other pharmaceutically effective agents such as drugs, antibiotics, wound healing agents and antioxidants.

Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof

The present invention provides therapeutic compositions containing lysophosphotidic acids, methods for making the compositions, and methods of using the compositions in the preservation and treatment of organs.

Synthesis of new fluidity-enhanced amphiphilic compounds for soluble protein two-dimensional crystallization purpose

The synthesis of new amphiphilic compounds is described. The structures are rationally designed for soluble protein two-dimensional (2D) crystallization purpose. Special attention is devoted to fluidity properties expected of resulting monolayers. A series of 13 compounds was prepared containing unsaturated, branched or fluorinated alkyl chains. Structures are either symmetrical or dissymmetrical and present a hydroxyl group as polar head, eventually complemented with two other 'secondary' hydrophilic functions. Copyright (C) 1999 Elsevier Science Ireland Ltd.